This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the development and evaluation of a microsphere-based formulation of the drug dolcanatide, either alone or in combination with the drug sildenafil, for the prevention of colitis-associated colorectal cancer. The total funding amount is $708,023, awarded from July 1, 2024 to June 30, 2026. The recipient organization is Nous Biosciences Inc., a for-profit small disadvantaged...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to support the development and clinical evaluation of CTO1681, a novel compound designed to prevent and mitigate cytokine release syndrome (CRS) in recipients of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The project aims to determine the preliminary efficacy of CTO1681 in preventing or reducing CRS and immune effector...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $838,162 to Averto Medical Inc., a medical device company located in Fremont, California, to conduct a clinical trial for their Coloseal ICD System. This novel minimally-invasive medical device is designed to eliminate the need for temporary ostomy surgery in approximately 90% of rectal cancer patients, potentially saving around $65,000 per patient and up to $7.8 billion annually in...
This R01 grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan aims to develop an engineered commensal bacterial strain to neutralize the oncogenic bacterial metabolite colibactin and prevent colorectal cancer. The $627,422 award will fund research over a 5-year period from May 2025 to April 2030 to optimize the surface display of the colibactin-neutralizing enzyme ClbS, evaluate the protective efficacy in human...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop an improved immunochemotherapy treatment for metastatic colorectal cancer (mCRC). The key objectives are to: Develop and characterize a nanoparticle carrier that can co-deliver small interfering RNA (siRNA) targeting the IRHOM1 protein and a chemotherapy agent (CPT-SAHA) to mCRC tumors. Investigate the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Enclear Therapies Inc. provides $295,851 in funding to develop and test a preclinical system for delivering chemotherapy agents, such as topotecan, to the cerebrospinal fluid (CSF) to treat cancer that has spread to the central nervous system. The key objectives are to: 1) further optimize a preclinical CSF extracorporeal flow system for administering subarachnoid chemotherapy, 2) test the...
The National Cancer Institute (NCI) awarded a $644,034 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel nanoparticle-based drug delivery platform called "Scintillating Nanoparticle Drug Depot (SCIDD)". The goal is to use SCIDD to control the sustained and localized release of chemotherapy drugs within irradiated tumor tissue, with the aim of improving local disease...
The U.S. National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Nuago Therapeutics Inc., a small disadvantaged business in Chicago, IL. The grant supports the "Development of a DISE-Inducing, Short RNA Therapeutic to Treat Ovarian Cancer" project from June 2025 to May 2026. The project aims to advance cancer treatment by developing an innovative short RNA therapeutic to target and treat ovarian cancer, which...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $606,839 to Weill Medical College of Cornell University to conduct research on the role of gut microbiota amino acid metabolism in cancer. The key objectives are to: 1) identify microbes and their genes that deplete intestinal amino acids and evaluate their impact on the tumor microenvironment and cancer progression; 2) elucidate the molecular mechanisms by which microbiota...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research Program (CFDA 93.395), provides $375,134 to the University of Colorado-Denver to investigate a novel approach to reduce the accumulation of chemotherapeutic nanomedicines in healthy tissues and improve the efficacy of cancer treatment. The key objectives are to characterize how the innate immune response, specifically the cytokine IFN-λ, can be leveraged to elicit tightening of healthy tissue...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Covira Surgical, Inc. to develop a first-in-class agent, CS-0003, for preventing chemotherapy-related gastrointestinal (GI) toxicities and lethal infections. CS-0003 is an orally administered, non-antibiotic phosphate-rich mucoadhesive polyethylene glycol that aims to preserve the beneficial gut microbiome while suppressing the proliferation of harmful pathogens. The funding will support animal studies to demonstrate the safety and efficacy of CS-0003 in ameliorating chemotherapy-induced toxicity and infection in mice. Successful completion of this Phase I project by the award end date of Aug 31, 2025 will provide evidence that CS-0003 can help reduce chemotherapy-related GI toxicities and infections, which are major causes of treatment disruptions, potential cancer progression, and increased mortality in cancer patients.